Six-Month Versus Nine-Month Anti-Tubercular Therapy for Tubercular Posterior Uveitis: A Multicenter, Randomized Controlled Trial
Issued Date
2025-01-01
Resource Type
ISSN
08820538
eISSN
17445205
Scopus ID
2-s2.0-105024875101
Pubmed ID
41363883
Journal Title
Seminars in Ophthalmology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Seminars in Ophthalmology (2025)
Suggested Citation
Ronnie Abhishek T., Ali M.H., Aung Win M.Z., Sukavatcharin S., Kelgaonkar A., Basu S. Six-Month Versus Nine-Month Anti-Tubercular Therapy for Tubercular Posterior Uveitis: A Multicenter, Randomized Controlled Trial. Seminars in Ophthalmology (2025). doi:10.1080/08820538.2025.2599224 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113632
Title
Six-Month Versus Nine-Month Anti-Tubercular Therapy for Tubercular Posterior Uveitis: A Multicenter, Randomized Controlled Trial
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: The benefits of anti-tubercular therapy (ATT) in treating ocular tuberculosis (TB) are well documented. However, the optimal duration of ATT remains uncertain. We assessed the efficacy of 6-month ATT compared to 9-month therapy in preventing recurrent intraocular inflammation. Design: Multi-center, open-label, non-inferiority, randomized controlled trial across three centers in India, Myanmar, and Thailand. Methods: Patients aged (Formula presented.) 18 years with tubercular posterior uveitis (retinal vasculitis, serpiginous-like choroiditis [SLC] or multifocal choroiditis) were randomized to receive either 6- or 9-month ATT. Systemic corticosteroids were mandatory for SLC and, at the treating physician’s discretion, for other phenotypes. The primary outcome measure was the non-recurrence of inflammation 1 year after ATT. Results: Sixty-four patients (64.1% males, median age 38 years [22–70], 43.8% bilateral) were randomized across the three sites during the study period. Thirty patients were assigned to the 6-month arm and 34 to the 9-month arm. Both treatments demonstrated a high non-recurrence rate on intention-to-treat (ITT) analysis (0.94 [0.79–0.99] for 9-month [n = 32] and 0.85 [0.65–0.96] for 6-month treatment [n = 26]). The difference in proportion remained below the non-inferiority margin (0.16) for both the ITT (0.09 [84% CI −0.02–0.2]) and per-protocol (0.13 [84% CI 0.01–0.25]) analyses. In subgroup analysis, retinal vasculitis appeared to favor 6-month ATT, and SLC 9-months, with the confidence intervals not deviating on bootstrap resampling. No discontinuation due to drug toxicity was reported in either group. Conclusion: Six-month ATT is non-inferior to 9-month ATT for treating tubercular posterior uveitis, though it may vary between the different clinical phenotypes.